RxDoctor Payments Data

Kendall Berghofer

Primary Care · Dearborn, MINPI 1215682448

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 63 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 14 manufacturers reported payments, led by ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) at 53.5% of the total.

$1,780in general payments, 2019–2025

Across 63 payments — averaging $28.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$953
  • GSK$301
  • Merck$95
  • Sanofi-aventis U.S. LLC$71
  • Pfizer$64
  • Alnylam Pharmaceuticals Inc.$56
  • plus $240 from 8 others

What the payments were for

  • Food & beverage$1,780100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,780 in reported general payments places this provider in the 80th percentile of 292 primary care providers in Michigan.

See all primary care providers in Michigan

Medicare billing

Part B allowed, 2024
$10,360
Medicare patients
87
Services billed
130

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban43$38,365
XareltoRivaroxaban19$12,220
Metoprolol Succinate54$705
Atorvastatin Calcium84$536
Ezetimibe24$384
Lisinopril52$373
Hydralazine Hcl34$363
Amlodipine Besylate72$346
Doxazosin Mesylate23$344
ClopidogrelClopidogrel Bisulfate19$280
Metoprolol Tartrate48$211
Losartan Potassium34$191
Isosorbide Mononitrate ErIsosorbide Mononitrate11$167
Carvedilol22$146
Furosemide23$82

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$64$38,36543 claims
Johnson & JohnsonXarelto$15$12,22019 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 292 primary care providers in Michigan.

Other primary care in Dearborn

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →